Effects of a Dedicated Inpatient Diabetes Management Service on Glycemic Control in a Community Hospital Setting.
diabetes
hospitalist
hyperglycemia
inpatient
length of stay
readmissions
Journal
Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
23
2
2021
medline:
29
10
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
Community hospitals account for over 84% of all hospitals and over 94% of hospital admissions in the United States. In academic settings, implementation of an Inpatient Diabetes Management Service (IDMS) model of care has been shown to reduce rates of hyper- and hypoglycemia, hospital length of stay (LOS), and associated hospital costs. However, few studies to date have evaluated the implementation of a dedicated IDMS in a community hospital setting. This retrospective study examined the effects of changing the model of inpatient diabetes consultations from a local, private endocrine practice to a full-time endocrine hospitalist on glycemic control, LOS, and 30-day readmission rates in a 267-bed community hospital. Overall diabetes patient days for the hospital were similar pre- and post-intervention (20,191 vs 20,262); however, the volume of patients seen by IDMS increased significantly after changing models. Rates of hyperglycemia decreased both among patients seen by IDMS (53.8% to 42.5%, Implementation of an endocrine hospitalist-based IDMS at a community hospital was associated with significantly decreased hyperglycemia, while avoiding concurrent increases in hypoglycemia. Further studies are needed to investigate whether these effects are associated with improvements in clinical outcomes, patient or staff satisfaction scores, or total cost of care.
Sections du résumé
BACKGROUND
Community hospitals account for over 84% of all hospitals and over 94% of hospital admissions in the United States. In academic settings, implementation of an Inpatient Diabetes Management Service (IDMS) model of care has been shown to reduce rates of hyper- and hypoglycemia, hospital length of stay (LOS), and associated hospital costs. However, few studies to date have evaluated the implementation of a dedicated IDMS in a community hospital setting.
METHODS
This retrospective study examined the effects of changing the model of inpatient diabetes consultations from a local, private endocrine practice to a full-time endocrine hospitalist on glycemic control, LOS, and 30-day readmission rates in a 267-bed community hospital.
RESULTS
Overall diabetes patient days for the hospital were similar pre- and post-intervention (20,191 vs 20,262); however, the volume of patients seen by IDMS increased significantly after changing models. Rates of hyperglycemia decreased both among patients seen by IDMS (53.8% to 42.5%,
CONCLUSIONS
Implementation of an endocrine hospitalist-based IDMS at a community hospital was associated with significantly decreased hyperglycemia, while avoiding concurrent increases in hypoglycemia. Further studies are needed to investigate whether these effects are associated with improvements in clinical outcomes, patient or staff satisfaction scores, or total cost of care.
Identifiants
pubmed: 33615858
doi: 10.1177/1932296821993198
pmc: PMC8120056
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
546-552Références
N Engl J Med. 2016 Sep 15;375(11):1009-11
pubmed: 27508924
Endocr Pract. 2006 Jul-Aug;12 Suppl 3:35-42
pubmed: 16905515
Circulation. 2008 Feb 26;117(8):1018-27
pubmed: 18268145
J Healthc Qual. 2016 Nov/Dec;38(6):e89-e96
pubmed: 26991349
J Am Coll Surg. 2007 Nov;205(5):704-11
pubmed: 17964447
Endocr Pract. 2014 Sep;20(9):870-5
pubmed: 24641928
Can J Diabetes. 2017 Feb;41(1):10-16
pubmed: 27658765
J Wound Ostomy Continence Nurs. 2008 Jul-Aug;35(4):397-404; quiz 405-6
pubmed: 18635989
Health Serv Res. 2003 Jun;38(3):905-18; discussion 919-22
pubmed: 12822918
J Community Hosp Intern Med Perspect. 2019 Apr 12;9(2):64-73
pubmed: 31044034
Am Fam Physician. 2010 May 1;81(9):1130-5
pubmed: 20433129
N Engl J Med. 1996 Aug 15;335(7):514-7
pubmed: 8672160
Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1405-1407
pubmed: 31399417
Diabetes Care. 1997 Oct;20(10):1553-5
pubmed: 9314634
J Clin Endocrinol Metab. 2019 Sep 1;104(9):3679-3691
pubmed: 31042288
Arch Intern Med. 2005 Apr 11;165(7):796-801
pubmed: 15824300
Endocr Pract. 2014 Apr;20(4):320-8
pubmed: 24246354
Diabetes Res Clin Pract. 2012 Nov;98(2):249-56
pubmed: 23036785
J Diabetes Sci Technol. 2020 Jul;14(4):780-782
pubmed: 32486900
Curr Diab Rep. 2015 Apr;15(4):17
pubmed: 25712258
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Neurocrit Care. 2009;11(1):56-63
pubmed: 19418265
Value Health. 2009 Mar-Apr;12(2):267-72
pubmed: 20667061
Am J Health Syst Pharm. 2012 Jul 15;69(14):1240-5
pubmed: 22761080
J Diabetes Sci Technol. 2020 Sep;14(5):928-944
pubmed: 32783456
Diabet Med. 2008 Feb;25(2):147-51
pubmed: 18201215
Am J Med. 1995 Jul;99(1):22-8
pubmed: 7598138
Jt Comm J Qual Patient Saf. 2012 May;38(5):195-206
pubmed: 22649859
Endocr Pract. 2010 May-Jun;16(3):512-21
pubmed: 20350921
BMJ Open Diabetes Res Care. 2018 Apr 5;6(1):e000460
pubmed: 29657719
Endocr Pract. 2006 Jul-Aug;12 Suppl 3:43-8
pubmed: 16905516
Chest. 2001 Feb;119(2):580-9
pubmed: 11171741
Curr Med Res Opin. 2015 Jan;31(1):107-14
pubmed: 25369567
Diabetes Res Clin Pract. 2007 Nov;78(2):211-6
pubmed: 17481769
Endocr Pract. 2019 Jun;25(6):612-615
pubmed: 31242127
Endocr Pract. 2006 Jul-Aug;12 Suppl 3:91-9
pubmed: 16905524
J Vasc Surg. 2017 Mar;65(3):819-825
pubmed: 27988160
Clin Diabetes Endocrinol. 2017 Mar 22;3:3
pubmed: 28702257
J Diabetes Complications. 2017 Jan;31(1):122-127
pubmed: 27838101